A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.

被引：0
|
作者：
Li, Huiping
Zhang, Jiayang
Yin, Rutie
Song, Nan
Zhang, Youzhong
Zhang, Yu
Zhang, Keqiang
Pan, Hongming
Wang, Ke
Lou, Ge
Li Guiling
Zhang, Ben
Wang, Quanren
Gao, Yunong
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Breast Oncol, Minist Educ Beijing, Beijing, Peoples R China
[2] Sichuan Univ, Dept Gynecol & Obstet, West China Univ Hosp 2, Chengdu, Peoples R China
[3] Sichuan Univ, West China Univ Hosp 2, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Dept Gynecol Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
[5] Shangdong Univ, Dept Obstet & Gynecol, Qilu Hosp, Shandong, Peoples R China
[6] Cent South Univ, Xiangya Hosp, Med Eth Comm, Changsha, Peoples R China
[7] Hunan Canc Hosp, Gynecol Oncol Ward 5, Changsha, Peoples R China
[8] Zhejiang Univ, Dept Med Oncol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China
[9] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[10] Harbin Med Univ, Gynecol Ward 1, Canc Hosp, Harbin, Peoples R China
[11] Huazhong Univ Sci & Technol, Union Hosp, Dept Gynecol Oncol, Tongji Med Coll, Wuhan, Peoples R China
[12] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
[13] Beijing Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5539
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer
    Sepideh Gholami
    Andrew Marano
    Nanhai G. Chen
    Richard J. Aguilar
    Alexa Frentzen
    Chun-Hao Chen
    Emil Lou
    Sho Fujisawa
    Clarisse Eveno
    Laurence Belin
    Pat Zanzonico
    Aladar Szalay
    Yuman Fong
    Breast Cancer Research and Treatment, 2014, 148 : 489 - 499
  • [22] A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer
    Gholami, Sepideh
    Marano, Andrew
    Chen, Nanhai G.
    Aguilar, Richard J.
    Frentzen, Alexa
    Chen, Chun-Hao
    Lou, Emil
    Fujisawa, Sho
    Eveno, Clarisse
    Belin, Laurence
    Zanzonico, Pat
    Szalay, Aladar
    Fong, Yuman
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (03) : 489 - 499
  • [23] Age impacts response to paclitaxel-anti-PDL1 combination therapy in triple-negative breast cancer.
    Spasic, Milos
    Goreczny, Gregory J.
    Guo, Qiuchen
    Hutchinson, John N.
    Freedman, Rachel A.
    Mittendorf, Elizabeth A.
    McAllister, Sandra S.
    CANCER RESEARCH, 2021, 81 (13)
  • [24] MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells
    Zeng, Xiaoqi
    Jiang, Shanshan
    Ruan, Simin
    Guo, Zhaoze
    Guo, Jingyun
    Liu, Minfeng
    Ye, Changsheng
    Dong, Jianyu
    MOLECULAR MEDICINE REPORTS, 2021, 24 (02)
  • [25] A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.
    Soliman, Hatem Hussein
    Han, Hyo S.
    Hogue, Deanna
    Mooney, Blaise
    Costa, Ricardo L.
    Lee, Marie Catherine
    Niell, Bethany
    Williams, Angela
    Chau, Alec
    Falcon, Shannon
    Khakpour, Nazanin
    Soyano, Aixa
    Armaghani, Avan J.
    Weinfurtner, Robert J.
    Hoover, Susan
    Kiluk, John
    Rosa, Marilin
    Fridley, Brooke
    Khong, Hung T.
    Czerniecki, Brian J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Combination of a PI3K-and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer
    Wulf, Gerburg M.
    Juvekar, Ashish
    Lyssiotis, Costas A.
    Hu, Hai
    Yadegarynia, Sina
    Liu, Hui
    Kim, Baek
    Winter, Eric
    Scully, Ralph
    Asara, John
    Cantley, Lewis C.
    Matulonis, Ursula
    CANCER RESEARCH, 2014, 74 (19)
  • [27] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
  • [28] Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial
    Loap, Pierre
    Loirat, Delphine
    Berger, Frederique
    Rodrigues, Manuel
    Bazire, Louis
    Pierga, Jean-Yves
    Vincent-Salomon, Anne
    Laki, Fatima
    Boudali, Latifa
    Raizonville, Laurence
    Mosseri, Veronique
    Jochem, Anne
    Eeckhoutte, Alexandre
    Diallo, Mamadou
    Stern, Marc-Henri
    Fourquet, Alain
    Kirova, Youlia
    JAMA ONCOLOGY, 2022, 8 (12) : 1802 - 1808
  • [29] Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
    Westin, Shannon N.
    Labrie, Marilyne
    Litton, Jennifer K.
    Blucher, Aurora
    Fang, Yong
    Vellano, Christopher P.
    Marszalek, Joseph R.
    Feng, Ningping
    Ma, XiaoYan
    Creason, Allison
    Fellman, Bryan
    Yuan, Ying
    Lee, Sanghoon
    Kim, Tae-Beom
    Liu, Jinsong
    Chelariu-Raicu, Anca
    Chen, Tsun Hsuan
    Kabil, Nashwa
    Soliman, Pamela T.
    Frumovitz, Michael
    Schmeler, Katheleen M.
    Jazaeri, Amir
    Lu, Karen H.
    Murthy, Rashmi
    Meyer, Larissa A.
    Sun, Charlotte C.
    Sood, Anil K.
    Coleman, Robert L.
    Mills, Gordon B.
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6354 - 6365
  • [30] Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer.
    Shah, Payal D.
    Zarrin, Haley
    Wethington, Stephanie
    Latif, Nawar
    Martin, Lainie
    Rodriguez, Diego
    Elkins, Katie
    Giuntoli, Robert
    Burger, Robert
    Tanyi, Janos
    Morgan, Mark
    Domchek, Susan M.
    Gailliard, Stephanie
    Armstrong, Deborah K.
    Simpkins, Fiona
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 75 - 75
12345